Cerus Corporation (CERS)

[mdimport]

I ran a 10-year chart on $CERS to find the bottom from a technical perspective: $0.60 on March 1, 2009.



Something doesn't gel with the commentary in the 8-k:

"...On May 23, 2017, Cerus Corporation (the "Company" or "Cerus") announced that it had received notification last week of a pending U.S. supply shortage of a platelet additive solution ("PAS") manufactured and sold by Fresenius Kabi Deutschland GmbH ("Fresenius Kabi"). The pending shortage is due to an unanticipated delay in U.S. Food and Drug Administration ("FDA") approval of a plastic component used in the manufacture of the PAS container following discontinuation of the original component by Fresenius Kabi's supplier. The shortage is expected to temporarily impact certain U.S. blood centers that utilize PAS to produce INTERCEPT platelets. Fresenius Kabi has stated that it is working with its suppliers and the FDA to resolve this delay and minimize any long-term disruption in supply. However, Cerus believes that the pending shortage could adversely affect INTERCEPT platelet production by impacted blood centers through year end. ..."

$CERS price decline also doesn't match the relatively small projected revenue declines: 4-12% depending on actuals.

"...As a result of the expected impact of the PAS supply disruption on INTERCEPT platelet production, the Company is updating its 2017 product revenue guidance to a range of $38 million to $46 million compared to the prior range of $43 million to $48 million. ..."